Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

27.06B

Market cap27.06B

Price-Earnings ratio

20.98

Price-Earnings ratio20.98

Dividend yield

—

Dividend yield—

Average volume

1.17M

Average volume1.17M

High today

$186.15

High today$186.15

Low today

$182.35

Low today$182.35

Open price

$183.16

Open price$183.16

Volume

383.90K

Volume383.90K

52 Week high

$202.41

52 Week high$202.41

52 Week low

$115.25

52 Week low$115.25

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $182.52. The company's market cap stands at 27.06B, with a P/E ratio of 20.98.

As of 2026-04-27, Biogen(BIIB) stock has fluctuated between $182.35 and $186.15. The current price stands at $182.52, placing the stock +0.1% above today's low and -2.0% off the high.

The Biogen(BIIB)'s current trading volume is 383.9K, compared to an average daily volume of 1.17M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $115.25.

BIIB News

TipRanks 3d

Biogen price target raised to $200 from $197 at BofA

BofA raised the firm’s price target on Biogen (BIIB) to $200 from $197 and keeps a Neutral rating on the shares ahead of Q1 results. Biogen’s first quarter shou...

Nasdaq 3d

Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?

Biogen BIIB will report first-quarter 2026 results on April 29, before market open. In the last reported quarter, the company's earnings beat expectations by 23...

Simply Wall St 4d

Biogen Gains China Felzartamab Rights As Valuation Gap Draws Attention

Biogen (NasdaqGS:BIIB) has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma. The deal consolidates global rights to felza...

Analyst ratings

53%

of 38 ratings

Buy

52.6%

Hold

42.1%

Sell

5.3%

More BIIB News

Nasdaq 5d

Biogen Q4 2024 Earnings Call Transcript

Biogen (NASDAQ: BIIB) Q4 2024 Earnings Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.